RESEARCH ARTICLE

Pregnancy outcomes in perinatally HIV-infected young women in Madrid, Spain: 2000-2015

Luis M. Prieto¹ *, Carolina Fernández McPhee², Patricia Rojas³, Diana Mazariégos⁴, Eloy Muñoz⁵, María José Mellado⁶, África Holguín⁷, María Luisa Navarro², María Isabel González-Tomé⁷, José Tomás Ramos⁴, on behalf of the Madrid Cohort of HIV-Infected Mother-Infant Pairs¶

1 Paediatrics Department, Hospital Universitario de Getafe, Madrid, Spain, 2 Infectious Diseases Unit, Paediatrics Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3 HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, Hospital Ramón y Cajal-IRYCIS and CIBER-ESP, Madrid, Spain, 4 Paediatrics Department, Hospital Clínico Universitario San Carlos, Madrid, Spain, 5 Obstetrics and Ginecology Department, Hospital Universitario 12 de Octubre, Madrid, Spain, 6 Tropical and Infectious Diseases Unit, Paediatrics Department, Hospital Universitario La Paz, Madrid, Spain, 7 Infectious Diseases Unit, Paediatrics Department, Hospital Universitario 12 de Octubre, Madrid, Spain

¶ Membership of the Madrid Cohort of HIV-Infected Mother-Infant Pairs is provided in the Acknowledgments.

* lmprieto.hugf@salud.madrid.org

Abstract

Background

An increasing number of perinatally HIV-infected women (PHIV) are reaching adulthood and becoming pregnant. Most PHIV women have been exposed to a high number of antiretroviral regimens, and they may have difficulties to achieve viral suppression. Psychosocial problems are not uncommon and could be an important barrier for treatment adherence. The effects of chronic HIV infection and long-term exposure to antiretroviral treatment of PHIV women cause concerns on the developing fetus. The aims of this study were to describe the prevention of mother-to-child transmission strategies in PHIV women and the infant outcomes in the Madrid Cohort of HIV-infected mother-infant pairs.

Methods

All PHIV pregnant women registered in the Cohort that gave birth from 2000 to 2015 were included in the study.

Results

Twenty-eight pregnancies in twenty-two perinatally infected women were registered. Most women were Caucasian and heavily treatment-experienced. Nine cases (32.1%) were at high risk of HIV mother-to-child transmission. Maternal HIV-1 viral load was detectable close to delivery in four women (14.3%). The management of these cases was described, and the treatment strategies were discussed. None of the newborns acquired HIV infection. Eight infants (28.6%) were small for gestational age.
Conclusions
This study included a large series of pregnancies among PHIV women attended according to a youth-centered care model. The challenges in the management of this population by health-care providers were described. Specific strategies to minimize perinatal transmission risks should be addressed in future collaborative studies.

Background
In Western European countries the efforts in the prevention of mother-to-child transmission of HIV (PMTCT) have led to an important reduction in the rates of new infections in children. [1–4] Cases of infection in children still occur, even if women were receiving antiretroviral treatment (ART) before conception, mainly due to detectable HIV plasma viral load as a consequence of drug resistance or poor maternal adherence to treatment. [5,6]

An increasing number of perinatally HIV-infected women (PHIV) are reaching adulthood and becoming pregnant. Most PHIV women have been exposed to a high number of antiretroviral regimens during pediatric care, and when they become pregnant, they may have difficulties to achieve viral suppression close to delivery. [7–10] Psychosocial problems are not uncommon in this population and could be an important barrier for treatment adherence. [11] The effects of chronic HIV infection and the long-term exposure to ART of PHIV women cause concerns on the developing fetus. [12,13] Moreover, little is known about the risk of HIV-MTCT in PHIV women and the specific clinical management of this population.

The aims of this study were to describe the PMTCT strategies in PHIV women and the infant outcomes in the Madrid Cohort of HIV-infected mother-infant pairs.

Methods
The Madrid Cohort of HIV-infected mother-infant pairs is a multicenter, prospective and observational study of HIV-1 infected women and their children. Since 2000, mother and infants pairs have been recruited from 8 hospitals in Madrid. The characteristics of the Cohort have been previously described elsewhere. [4]

All PHIV pregnant women registered in the Madrid Cohort who gave birth from 2000 to 2015 were included in the study. Data from PHIV pregnant women since the first visit for pregnancy monitoring until delivery, and data from their infants at birth and during a follow-up period up to 24 months of age were analyzed. Infants were considered HIV-uninfected if they had at least two negative HIV-1 RNA tests, one of them after the age of 3 months. These results were confirmed with at least one HIV-1 antibody assay at the age of 12 to 18 months.

Additionally, the characteristics of PHIV women before pregnancy were requested and obtained from two observational Cohorts: the Madrid Cohort of HIV-infected children and the Spanish Cohort of HIV-infected children and adolescents (CoRISPE). [14,15]

Women were considered to have acquired the HIV infection perinatally if they were diagnosed during childhood in the absence of other risk factors and if their own mothers had been also considered as HIV-infected.

Antiretroviral triple class resistance (TC-DRM) was defined as the extensive drug resistance to the three main antiretroviral families for HIV treatment, where the presence of genotypic resistance mutations was observed for at least one drug from each antiretroviral class [nucleos (t)ide reverse transcriptase inhibitors (NRTIs) non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors (PIs)].
High risk factors for HIV mother-to-child transmission were defined as one or more of the following: (1) a plasma HIV-1 RNA (viral load) higher than 200 copies/mL in two consecutive samples after week 28 of pregnancy (VF after 28 weeks), (2) or any detectable viral load close to delivery, (3) or harbouring TC-DRM. [16]

Newborns were considered small for gestational age (SGA) when birth weight was lower than <10th percentile based on Spanish gender-specific standards. [17] Congenital anomalies at birth were recorded and classified according to EUROCAT (European Surveillance of Congenital Anomalies). [18]

The study was approved by the Institutional Review Board at Hospital Universitario de Getafe, Madrid, Spain.

Results

Feature of the study population during pregnancy and delivery

Twenty-eight pregnancies were recorded among twenty-two perinatally-infected women, corresponding to twenty-two first pregnancies and six second pregnancies; all singleton. An integrated management of the pregnant women by the Infectious Diseases, Obstetrics and Paediatrics Department was carried out in all but one case. PHIV women were assisted by psychologist during their visits to the Clinics. The maternal characteristics at conception are described in Table 1. Most women were Caucasian and were heavily ART-experienced.

Nine women (32.1%) were not on ART at the time of conception but it was initiated during pregnancy in eight of these cases. Three of these women had a CD4 count below 200 cells/mm$^3$.

Table 1. Characteristics of 22 perinatally HIV-1 infected women at conception.

| PHIV women characteristics |  |
|-----------------------------|--|
| Ethnicity; n (%)            |  |
| Caucasian                   | 21 (95.4) |
| Sub-Saharan                 | 1 (4.5)   |
| Age at first conception (years); median (range) | 20 (18–21) |
| Previous AIDS diagnosis; n (%) | 6 (27.3) |

| Characteristics at conception of 28 pregnancies |  |
|--------------------------------------------------|--|
| Number of previous ART regimens; n (%)          |  |
| 1–2                                              | 3 (10.7) |
| 3–5                                              | 5 (17.9) |
| ≥ 6                                              | 20 (71.4) |
| On ART; n (%)                                   | 18 (64.3) |
| CD4 counts; n (%)                                |  |
| < 200 cells/mm$^3$                              | 3 (10.7) |
| 200–499 cells/mm$^3$                            | 7 (25.0) |
| > 500 cells/mm$^3$                              | 17 (60.7) |
| Unknown                                         | 1 (3.6) |
| Viral load (copies/mL); n (%)                    |  |
| ≤ 50                                            | 14 (50.0) |
| 51–999                                          | 4 (14.3) |
| 1000–9999                                       | 2 (7.1) |
| ≥ 10000                                         | 8 (28.6) |

PHIV, perinatally infected women with HIV; n, number; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral treatment; CD4, lymphocyte T CD4; c/ml, HIV-1 RNA copies per milliliter of plasma.

https://doi.org/10.1371/journal.pone.0183558.t001
The mode of delivery and the pregnancy outcomes are shown in Table 2. There were eight cases of SGA (28.6%). All but one patient were born at term (S1 Table). No birth defects were observed. No cases of perinatal HIV transmission were recorded during the children follow-up.

Detectable VL and presence of resistant viruses during pregnancy

There were 9 cases of high risk for HIV mother-to-child transmission, TC-DRM were documented in three women. In all TC-DRM cases a salvage regimen led to undetectable viral load close to delivery. The characteristics of these cases are summarized in Table 3.

Four out of six PHIV pregnant women under virological failure after 28 weeks of gestation were not on ART before conception. Although these pregnancies were recognized early, HIV viral load was not fully suppressed at week 28 in all cases. There was a patient who rejected antiretroviral treatment and psychosocial support. Among the other patients, viral load was closely monitored and treatment options were discussed. In four of them a new antiretroviral drug was added including raltegravir. Finally, two of them achieved undetectable viral load close to delivery. Overall, maternal viral load was detectable close to delivery in four women (14.3%). In these four cases, elective cesarean section was the mode of delivery and infants received a combination of three drugs as postnatal prophylaxis.

Discussion

Our study showed that the situation of PHIV women in Madrid who became pregnant was challenging. They were very young at the time of first conception, with treatment adherence

---

Table 2. Delivery characteristics and outcomes of 28 pregnancies outcomes from 22 perinatally HIV-1 infected women.

| Delivery characteristics | Number of deliveries 28 |
|--------------------------|-------------------------|
| Mode of delivery:        |                         |
| Vaginal; n (%)           | 15 (53.6)               |
| Elective Caesareaen section; n (%) | 11 (39.3)             |
| Acute Caesareaen section; n (%) | 2 (7.1)                |
| ZDV intrapartum; n (%)   | 24 (85.7)               |

| Pregnancy outcomes |
|---------------------|
| Newborn sex male; n (%) | 18 (64.3) |
| Gestational age, median weeks (IQR) | 38 (37–40) |
| Gestational age at birth < 37 weeks; n (%) | 1 (3.6) |
| Birth weight (g); median (IQR) | 2920 (2585–3142) |
| Birth weight; n (%): |                      |
| < 2500 g             | 5 (17.9)              |
| < 1500 g             | 0                     |
| Small for gestational age (%) | 8 (28.6)             |
| Breastfeeding; n (%) | 0                     |
| Postnatal child prophylaxis; n (%): |              |
| Monotherapy          | 22 (78.6)             |
| Dual or triple therapy | 6 (21.4)            |
| None                 | 0                     |
| MTCT rate; n (%)     | 0                     |

IQR, interquartile range; MTCT, mother-to-child transmission; ZDV, zidovudine.

https://doi.org/10.1371/journal.pone.0183558.t002
Table 3. Description of high risk cases for HIV mother-to-child transmission.

| Age at delivery (years) | Year of delivery | ART at conception | Number of previous ART regimens | Previous-to-start/switch HIV-1 RNA VL (copies/ml) | TC-DRM | ART during pregnancy | CD4 count at delivery (cells/mm³) | GA at delivery | HIV-1 RNA VL at delivery (copies/mL) | Mode of delivery | Infant prophylaxis |
|-------------------------|------------------|-------------------|--------------------------------|-----------------------------------------------|---------|----------------------|---------------------------------|----------------|------------------------------------|-----------------|---------------------|
| 22                      | 2007             | ABC+ TDF + ATV/r  | 7                              | <50                                           | No      | Stop ARV on week 5+5. Start ABC + 3TC + TDF + LPV/r on week 16 +1. | 899               | 38+1                       | 413             | 492                  | EMCS            | ZDV                 |
| 20                      | 2009             | No treatment     | 10                             | 51284                                        | No      | Start with ZDV + 3TC + LPV/r on week 12. Switch to ZDV + 3TC + ATV/r + RAL + T20 on week 29+6 because of VF. | 561               | 37+2                       | <20             | 561                  | EMCS            | ZDV                 |
| 19                      | 2010             | No treatment     | 6                              | 5700                                         | Yes     | Start with RAL + DRV/r + T20 on week 16 +5. | 664               | 38                         | <20             | 664                  | EMCS            | ZDV                 |
| 21                      | 2011             | No treatment     | 6                              | Unknown                                      | No      | No treatment          | Unknown                       | 38+0           | 44977                | EMCS            | ZDV                 |
| 16                      | 2012             | ABC+ ETV + DRV/r | 7                              | 36700                                        | Yes     | ABC + ETV + DRV/r     | 377               | 36+6                       | <50             | 377                  | EMCS            | ZDV + 3TC + NVP*    |
| 21                      | 2013             | FTC+ TDF + ATV/r | 8                              | 435                                          | No      | Switch to FTC + TDF + ATV/r + RAL + MRV on week 37+1 because of VF. | 307               | 39+4                       | <50             | 307                  | EMCS            | ZDV + 3TC + NVP    |
| 22                      | 2013             | No treatment     | 5                              | 32240                                        | No      | Start with FTC + TDF + LPV/r on week 4. Switch to TDF + FTC + DRV/r + RAL + MVC on week 23 +4 because of VF. | 65                | 37+4                       | 24300           | 65                   | EMCS            | ZDV + 3TC + NVP    |
| 18                      | 2014             | FTC + TDF + LPV/r| 7                              | 24709                                        | Yes     | Switch to FTC + TDF + ETV + DRV/r + RAL on Week 16 +6. | 563               | 38+2                       | <20             | 563                  | EMCS            | ZDV                 |
| 25                      | 2014             | No treatment     | 14                             | 183200                                       | No      | Start with 3TC + ABC + DRV/r on week 7. Switch to 3TC + ABC + DRV/r + RAL on week 28+2 because of VF. | 130               | 37+2                       | 657             | 130                  | EMCS            | ZDV + 3TC + NVP    |

* When maternal viral load close to delivery was known and resulted undetectable, the neonate was switched from the 3-drug combination prophylaxis to a 4-week ZDV regimen.

VL, viral load; c/ml, HIV-1 RNA copies/ml; TC-DRM, presence of drug resistance mutations to the three main ARV families (NNRTI, NRTI and PI) in viruses. GA, gestational age; TC-DRM, antiretroviral triple class resistance; ELCS, elective cesarean section; EMCS, emergency cesarean section; CD4, CD4 count; ART, antiretroviral therapy; TC-DRM, presence of drug resistance mutations to the three main ARV families (NNRTI, NRTI and PI) in viruses. GA, gestational age; TC-DRM, antiretroviral triple class resistance; ELCS, elective cesarean section; EMCS, emergency cesarean section; ETV, etravirine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; LPV/r, lopinavir/ritonavir; MRV, maraviroc; NVP, nevirapine; RAL, raltegravir; T20, enfuvirtide; VL, viral load; ZDV, zidovudine.

https://doi.org/10.1371/journal.pone.0183558.t003
problems as previously described for this population, and also heavily ART-exposed. A high percentage of these women had detectable HIV-1 viral load at conception, and one third of them were on a high risk situation for HIV-1 transmission to their newborns. However, reassuringly, most of the women achieved an undetectable HIV-1 viral load close to delivery and there were not cases of HIV-1 transmission to the second generation. Another observation of our study was the high proportion of SGA newborns in our cohort, even though only one child was born prematurely.

An increasing number of PHIV young people are reaching adulthood throughout Europe. [19] HIV-infected youth may face barriers for treatment adherence and retention in care. [20] Psychosocial barriers, but also, stigma, social or family support and socioeconomic status can impact the long-term outcomes of this population. [21] Moreover, the consequences of long-term exposure to antiretroviral drugs, the use of suboptimal therapies during their childhood, and the effects of chronic inflammation and the immune activation are unknown for both the mothers and the exposed newborns.

It is common that perinatally HIV-infected youth started to be sexually active while still under the care of paediatric health services. [22,23] When analysed, perinatally HIV-infected youth have not always had an adequate knowledge about their disease. [23] Unprotected sexual intercourse may be not so uncommon, leading to unintended pregnancies. [23,24] The discussions with HIV-infected adolescents may not focus only on the prevention of sexually transmitted infections but also on family planning. [25] Preconception care and counseling are very important for pregnancy planning but also to ensure that perinatally infected women are on effective ART to avoid HIV transmission to their partners and their future children. [26]

Nine women (33.4%) were not on ART at conception. Previous reports have showed that it is not uncommon that PHIV women were not receiving ART at conception. An analysis of 44 PHIV pregnant women from the United Kingdom and Ireland showed that only 71% of pregnant women were on ART before gestation. [27] Psychosocial barriers and stigma could be the most important factor in treatment adherence for them. [28] Previous studies from the Madrid Cohort also showed that there were significant and complex psychosocial problems in perinatally HIV-infected youth. [23] Psychosocial and emotional support may be a key element to embrace ART by women once pregnancy is recognized and to improve adherence rates. In this study, six out of the nine women who started ART in pregnancy, achieved an undetectable HIV-1 RNA viral load close to delivery.

High risk situations of HIV-1 transmission, defined as TC-DRM, virological failure after week 28 of pregnancy and detectable HIV-1 viral load close to delivery, were also common. For these situations, an individual approach in the selection of ART regimens in combination with psychosocial support could be useful. The use of new antiretroviral drugs as salvage therapies based on the results of the genotypic resistance tests in women with TC-DRM should be considered. Integrase inhibitors may play an important role in achieving a more rapid decline in plasma viral load to undetectable levels. However, there were four cases of pregnant women with non-suppressed HIV viral load close to delivery. Strategies to optimize adherence, including the consideration of the women preferences, are crucial and may be challenging in high risk situations. Elective Caesarean section and combined neonatal prophylaxis could also be very important measures to avoid HIV-1 transmission. [29]

Special attention has been focused on models that integrate obstetrics and mental health services into the HIV care setting for meeting the needs of PHIV pregnant women. [30] This series also showed the results of a multidisciplinary approach for these PHIV pregnant women, with includes the coordinated action of HIV, obstetrics and mental health care providers previously experienced in HIV-infected youth. The team tried to give an integrated response to the special needs and concerns of each woman and could be useful for reaching
better outcomes. However, this observational study could not evaluate the real impact of this youth-centered model in the outcomes of PHIV pregnant women.

In previous studies there were not important gender disparities in HIV-exposed infants, [3,4] although it has been published that the risk of acquisition of HIV may be higher for female infants than for male ones. [31,32] A high rate of male infants (64%) born from PHIV women has been observed in this study. However, the interpretation of this result requires considerations. Firstly, the number of PHIV women and infants included were small, and secondly, the rates of miscarriage or termination of pregnancies were not analyzed in this study. To our knowledge, previous studies on PHIV pregnant women have not well assessed this topic. The gender of these infants may be further evaluated in PHIV women studies.

Prematurity and fetal growth restrictions leading to low birth weight have been associated with an overall increase of neonatal and long-term morbidity and mortality in neonates. [33,34] The rates of SGA among neonates from PHIV women in this study (28.6%) were higher than expected when compared to non-HIV-infected young women in Spain. [35] In a previous report from US, the SGA risk was higher in PHIV women compared to behaviorally acquired HIV-infected women [adjusted OR of 5.7 (95% CI = 1.03–31.61)]. [12] Although the numbers are small to draw conclusions, it may be a matter of concern if confirmed in other studies with larger number of PHIV women. Further studies are needed to determine the causal mechanisms and the possible role of long-term exposure to ART [36] and chronic inflammation. [37] HIV-exposed children born SGA may thus warrant an appropriate follow-up throughout adulthood.

There are several limitations to our study. The number of pregnancies reported makes our findings entirely descriptive. In this study we were unable to address whether the pregnancies were planned or not, and how this could affect the outcomes. We have neither analyzed the rate or causes of previous miscarriages or stillbirths. The use of illicit drugs or tobacco during pregnancy was not assessed. We did not either specifically assess obstetric complications such as gestational diabetes or comorbidities such as sexually transmitted infections.

In summary, this study provides a large series of pregnancies in PHIV women, reflecting some challenges and programmatic implications of this unique population for health-care providers. The characteristics and outcomes of these PHIV women attended according to a youth-centered care model were described. Additionally to this model, specific strategies should be addressed in future or collaborative studies in order to improve the management of high-risk patients for HIV-1 transmission and thus minimize the vertical transmission rate.

Supporting information
S1 Table. Baseline characteristics of HIV-exposed newborns.
(DOCX)

Acknowledgments
Members of the Madrid Cohort of HIV-Infected mother-infant Pairs

• Hospital Universitario 12 de Octubre: MI González-Tomé, E Muñoz, D Blázquez, P Rojo, R García, R Rubio, F Pulido.

• Hospital Universitario La Paz: JM Peña, M González, MJ Mellado, L Escosa.

• Hospital General Universitario Gregorio Marañón: ML Navarro, J Saavedra, MDn Gurbindo, MC Viñuelas, P Miralles, C Fernández McPhee.
Author Contributions

Conceptualization: Luis M. Prieto, Carolina Fernández McPhee, Patricia Rojas, Diana Mazariegos, Eloy Muñoz, María José Mellado, África Holguín, María Luisa Navarro, María Isabel González-Tomé, José Tomás Ramos.

Data curation: Luis M. Prieto, Carolina Fernández McPhee, Patricia Rojas, Diana Mazariegos, Eloy Muñoz, María José Mellado, África Holguín, María Luisa Navarro, María Isabel González-Tomé, José Tomás Ramos.

Formal analysis: Luis M. Prieto, Carolina Fernández McPhee, Patricia Rojas, Diana Mazariegos, María Isabel González-Tomé, José Tomás Ramos.

Investigation: Luis M. Prieto, José Tomás Ramos.

Methodology: Luis M. Prieto, María Isabel González-Tomé, José Tomás Ramos.

Project administration: María Isabel González-Tomé, José Tomás Ramos.

Supervision: Eloy Muñoz, María José Mellado, África Holguín, María Luisa Navarro, José Tomás Ramos.

Validation: Eloy Muñoz, María José Mellado, África Holguín, María Luisa Navarro, María Isabel González-Tomé, José Tomás Ramos.

Visualization: María Isabel González-Tomé.

Writing – original draft: Luis M. Prieto, Carolina Fernández McPhee, Patricia Rojas, María Isabel González-Tomé, José Tomás Ramos.

Writing – review & editing: Luis M. Prieto, Carolina Fernández McPhee, Patricia Rojas, Diana Mazariegos, María Isabel González-Tomé, José Tomás Ramos.

References

1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005; 40:458–65. https://doi.org/10.1086/427287 PMID: 15668871

2. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008; 22:289–99. https://doi.org/10.1097/QAD.0b013e3282f3d69c PMID: 18097232

3. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008; 22:973–81 https://doi.org/10.1097/QAD.0b013e3282f9b67a PMID: 18453857

4. Prieto LM, González-Tomé MI, Muñoz E, Fernández-Ibieto M, Soto B, Del Rosal T, et al. Low rates of mother-to-child transmission of HIV-1 and risk factors for infection in Spain: 2000–2007. Pediatr Infect Dis J. 2012; 31:1053–8. https://doi.org/10.1097/INF.0b013e31826fe968 PMID: 22926219
5. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS. 2014; 28:1049–57. https://doi.org/10.1097/QAD.0000000000000212 PMID: 24560097

6. Tubiana R, Le Chenedec J, Rouzioux C, Mandelbrot L, Hamrene K, Dolfus C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis. 2010; 50:585–96. https://doi.org/10.1086/650005 PMID: 20070234

7. Cruz ML, Cardoso CA, João EC, Gomes IM, Abreu TF, Oliveira RH, et al. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS. 2010; 24:2727–31. https://doi.org/10.1097/QAD.0b013e32833e50d4 PMID: 20827164

8. Kenny J, Williams B, Prime K, Tookey P, Foster C. Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV. HIV Med. 2012; 13:304–8- https://doi.org/10.1111/j.1468-1293.2011.00967.x PMID: 22136754

9. Calitri C, Gabiano C, Galli L, Chiappini E, Giaquinto C, Buffolano W, Genovese O, et al. The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection. BMC Infect Dis. 2014 May 20; 14:277 https://doi.org/10.1186/1471-2334-14-277 PMID: 24886649

10. Badell ML, Kachikis A, Haddad LB, Nguyen ML, Lindsay M. Comparison of pregnancies between perinatally and sexually HIV-infected women: an observational study at an urban hospital. Infect Dis Obstet Gynecol. 2013; 2013:10763 https://doi.org/10.1155/2013/10763 PMID: 24106419

11. Millery M, Vazquez S, Walther V, Humphrey N, Schlecht J, Van Devanter N. Pregnancy in Perinatally HIV-Infected Young Women and Implications for Care and Service Programs. J Assoc Nurses AIDS Care. 2012; 23:41–51. https://doi.org/10.1016/j.jana.2011.05.008 PMID: 21820325

12. Jao J, Sigel KM, Chen KT, Rodriguez-Caprio G, Posada R, Shust G, et al. Small for Gestational Age Birth Outcomes in Pregnant Women with Perinatally Acquired HIV. AIDS. 2012; 26:855–9. https://doi.org/10.1097/QAD.0b013e328351f6ef PMID: 22313958

13. Jao J, Agwu A, Mhango G, Kim A, Park K, Posada R, et al. Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women. AIDS. 2015; 29:111–16. https://doi.org/10.1097/QAD.0000000000000501 PMID: 25562495

14. de Jose MI, Jiménez de Ory S, Espiau M, Fortuny C, Navarro ML, Soler-Palacin P, et al. A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoR-ESpe). BMC Infect Dis. 2013 Jan 2; 13:2. https://doi.org/10.1186/1471-2334-13-2 PMID: 23282073

15. Palladino C, Briz V, Beliñon JM, Climent FJ, de Ory SJ, Mellado MJ, et al. Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012. PLoS One. 2014 May 1; 9(5):e96307. https://doi.org/10.1371/journal.pone.0096307 PMID: 24788034

16. Bailey H, Townsend CL, Cortina-Borja M, Thorne C; European Collaborative Study in EuroCoord. Improvements in virological control among women conceiving on combination antiretroviral therapy in Western Europe. AIDS. 2013; 27:2312–5. https://doi.org/10.1097/QAD.0b013e32833e50d4 PMID: 23736151

17. SEEP: Sociedad Española de Endocrinología Pediátrica. Estudios españoles de crecimiento 2010. Disponible en http://www.seep.es/privado/documentos/Publicaciones/Estudios_Esp%C3%B1oles_de_Crecimiento_2010.pdf [Accessed July 6, 2016].

18. EUROCAT: European Surveillance of Congenital Anomalies. Disponible en: http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/malformationcodingguides [Accessed July 6, 2016].

19. Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord. Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. Euro Surveill. 2016; 21(10).

20. Lali P, Lim SH, Khairuddin N, Kamarulzaman A. Review: An urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations. J Int AIDS Soc. 2015; 18:19393. https://doi.org/10.7448/IAS.18.2.19393 PMID: 25724503

21. Fish R, Judd A, Jungmann E, O’Leary C, Foster C; HIV Young Persons Network (HYPNet). Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit. HIV Med. 2014; 15:239–44. https://doi.org/10.1111/hiv.12091 PMID: 24112550

22. Croucher AP, Jose S, McDonald S, Foster C, Fidler S. Sexual and reproductive health in a UK cohort of young adults perinatally infected with HIV. Sex Transm Infect. 2013; 89:392–4. https://doi.org/10.1136/sексtrans-2012-050831 PMID: 23434788
23. Medin G, García-Navarro C, Navarro Gomez M, Ramos Amador JT, Mellado MJ, Jimenez S, et al. Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. AIDS Care. 2016; 28:124–30.

24. Badell ML, Lindsay M. Thirty years later: pregnancies in females perinatally infected with human immunodeficiency virus-1. AIDS Res Treat. 2012; 2012:418630; https://doi.org/10.1155/2012/418630 PMID: 22970353

25. Albright JN, Fair CD. Providers caring for adolescents with perinatally-acquired HIV: current practices and barriers to communication about sexual and reproductive health. AIDS Patient Care STDS. 2014; 28:587–593. https://doi.org/10.1089/apc.2014.0162 PMID: 25290765

26. Echenique M, Rodríguez VJ, LaCabe RP, Privette CK, Jones DL, Potter JE, et al. Behaviorally and perinatally HIV-infected young women: targets for preconception counseling. AIDS Care. 2017; 29:372–377. https://doi.org/10.1080/09540121.2016.1220483 PMID: 27535165

27. Byrne L, Thorne C, Foster C, Tookey P. Pregnancy outcomes in women growing up with perinatal acquired HIV in the United Kingdom and Ireland. J Int AIDS Soc. 2015, 17:19693 (abstr).

28. Elgalib A, Hegazi A, Samarawickrama A, Roedling S, Tariq S, Draeger E, et al. Pregnancy in HIV-infected teenagers in London. HIV Medicine. 2011; 12:118–123. https://doi.org/10.1016/j.hivmed.2010.08.010 PMID: 20807252

29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. [Accessed Sept 4, 2016].

30. Millery M, Vazquez S, Walther V, Humphrey N, Schlecht J, Van Devanter N. Pregnancies in perinatally HIV-infected young women and implications for care and service programs. J Assoc Nurses AIDS Care. 2012; 23:41–51. https://doi.org/10.1016/j.janc.2011.05.008 PMID: 21820325

31. Taha TE, Nour S, Kumwenda NJ, Broadhead RL, Fiscus SA, Kafulafula G, et al. Gender differences in perinatal HIV acquisition among African infants. Pediatrics. 2005; 115:e167–72. https://doi.org/10.1542/peds.2004-0159 PMID: 15687425

32. Thorne C, Newell ML; European Collaborative Study. Are girls more at risk of intrauterine-acquired HIV infection than boys?. AIDS. 2004; 18:344–7. PMID: 15075561

33. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med. 1999; 340:1234–1238. https://doi.org/10.1056/NEJM199904223401603 PMID: 10210706

34. Strauss RS. Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort. JAMA. 2000; 283:625–632. PMID: 10665702

35. Subirats I, Pérez G, Rodríguez-Sanz M, Salvador J, Jané M. Recent Immigration and Adverse Pregnancy Outcomes in an Urban Setting in Spain. Matern Child Health J. 2011; 15:561–9. https://doi.org/10.1007/s10995-010-0614-7 PMID: 20440546

36. Hernandez S, Moren C, Catalán-García M, Lopez M, Guitart-Mampel M, Coll O, et al. Mitochondrial toxicity and caspase activation in HIV pregnant women. J Cell Mol Med. 2016 [Epub ahead of print]

37. López M, Figueras F1, Coll O, Gonçó A, Hernández S, Lonçá M et al. Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery. J Infect Dis. 2016; 213:343–50. https://doi.org/10.1093/infdis/jiv416 PMID: 26265778